Analysis of dermatomyositis‐specific autoantibodies and clinical characteristics in Japanese patients
Authors:
- 26 August 2011
- journal article
- research article
- Published by Wiley in The Journal of Dermatology
- Vol. 38 (10) , 973-979
Abstract
Dermatomyositis (DM) is an idiopathic systemic inflammatory disease that is often accompanied by interstitial lung disease (ILD) or internal malignancy. New autoantibodies, anti‐clinically amyopathic dermatomyositis 140 (anti‐CADM‐140) antibody (Ab) and anti‐155/140 Ab, as well as anti‐aminoacyl‐tRNA synthetase (anti‐ARS) Ab and anti‐Mi‐2 Ab, have been discovered and their utility indicated. However, the association between these autoantibodies and the clinical characteristics of DM is not fully understood, and it is unclear whether anti‐155/140 Ab is “specific” to DM patients with internal malignancy. Therefore, we analyzed 55 DM patients and 18 non‐DM patients with malignancy to evaluate the clinical characteristics, especially skin manifestations, in association with DM‐specific autoantibodies detected by immunoprecipitation. Six patients (11%) had anti‐CADM‐140 Ab, nine (16%) had anti‐155/140 Ab, eight (15%) had anti‐ARS Ab and six (11%) had anti‐Mi‐2 Ab. The frequency of DM patients positive for any type of autoantibody was 53%. Among the 20 DM patients with ILD, three (15%) had both anti‐CADM‐140 Ab and rapidly progressive ILD, and required intensive therapy (P < 0.05). ILD found in anti‐ARS Ab‐positive patients did not progress rapidly. The prevalence of muscle involvement in patients with anti‐CADM‐140 Ab was 83%. Among the 18 DM patients with internal malignancy, four (22%) had anti‐155/140 Ab, and internal malignancy was found in four cases (44%) of nine anti‐155/140 Ab‐positive patients. None of the non‐DM patients with malignancy were positive for anti‐155/140 Ab. In conclusion, the results of the present study indicate that anti‐155/140 Ab is specific to DM patients with internal malignancy and that we may be able to predict prognosis of ILD and the presence of malignancy to some extent, suggesting that examination of autoantibodies in DM patients is clinically very useful. However, further investigation is needed because several findings differ from those of previous reports.Keywords
This publication has 29 references indexed in Scilit:
- Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositisBMC Musculoskeletal Disorders, 2010
- Association of distinct clinical subsets with myositis‐specific autoantibodies towards anti‐155/140‐kDa polypeptides, anti‐140‐kDa polypeptides, and anti‐aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single‐centre, cross‐sectional studyScandinavian Journal of Rheumatology, 2009
- Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesisCurrent Opinion in Rheumatology, 2008
- The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositisAnnals of the Rheumatic Diseases, 2007
- Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathiesAutoimmunity, 2006
- Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositisJournal of Dermatological Science, 2005
- Cutaneous markers of internal malignancy. II. Paraneoplastic dermatoses and environmental carcinogensJournal of the American Academy of Dermatology, 1993
- Cutaneous markers of internal malignancy. I. Malignant involvement of the skin and the genodermatosesJournal of the American Academy of Dermatology, 1993
- A New Approach to the Classification of Idiopathic Inflammatory MyopathyMedicine, 1991
- Multiplicity of antibodies in myositis seraArthritis & Rheumatism, 1984